Innocoll AG (NASDAQ:INNL) has tumbled 46.62% during the past week and has dropped 19.89% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 45.98%. Innocoll AG (NASDAQ:INNL) has underperformed the index by 20.62% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Innocoll AG (NASDAQ:INNL): The stock opened at $7.02 on Friday but the bulls could not build on the opening and the stock topped out at $7.02 for the day. The stock traded down to $5.77 during the day, due to lack of any buying support eventually closed down at $6.00 with a loss of -18.14% for the day. The stock had closed at $7.33 on the previous day. The total traded volume was 1,940,435 shares.
The company shares have dropped -59.73% from its 1 Year high price. On Jun 26, 2015, the shares registered one year high at $15.25 and the one year low was seen on Jun 17, 2016. The 50-Day Moving Average price is $8.82 and the 200 Day Moving Average price is recorded at $8.40.
Many analysts have stated their opinion on the company shares. Janney Capital initiates coverage on Innocoll AG (NASDAQ:INNL) In a research note issued to the investors, the brokerage major announces price-target of $15 per share.The shares have been rated Buy. The rating by the firm was issued on April 28, 2016. Institutional Investors own 38.47% of Innocoll AG shares.
Innocoll AG, formerly Innocoll GmbH, is a global, commercial-stage, specialty pharmaceutical company, with late-stage development programs. The Companys lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections, or DFIs. The Company has initiated Phase III efficacy trials for Cogenzia in both the United States and Europe. The Company has initiated a pivotal pharmacokinetic study for XaraColl. CollaGUARD, which prevents post-surgical adhesions, is approved in 48 countries in Europe, Asia, the Middle East and Latin America. The Company products consist of CollatampG surgical implant, RegenePro, Durieva and Septocoll, in a range of topical and implantable forms, including sponges, films, membranes and gels, compatible with a range of therapeutics, including hydrophobic and hydrophilic active ingredients and small molecules and biologics. It also offers CollaCare Suite for wound care.